TickerTalks
Browse all tickers →
TickerTalks›$NMRA
NMNMRA

Neumora Therapeutics, Inc. Common Stock

$NMRA·$289M·Biotechnology·Healthcare
$1.51-1.3%YTD-16.6%1Y+93.6%
Mentions · last 7 days
0
Price updated 12h ago
NMNMRA
Neumora Therapeutics, Inc. Common Stock$NMRA
$1.51-1.31%0 posts
AI analysisFundamentalsVoices on X
Loading…

Sentiment on XAI analysisGenerated by AI from underlying data

Top X posts

How loud the X conversation is around $NMRA and which way it's leaning — read in seconds.

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment7 posts analyzed · as of 2026-06-18

Neumora Therapeutics scrapped its depression drug navacaprant after Phase 3 KOASTAL-2 and KOASTAL-3 both missed primary endpoints, with the stock down roughly 50%. Posters frame management as having thrown good money after bad running two Phase 3s on a failed 2b in the most crowded CNS market. The remaining NLRP3 Inhibitor Program updates in August become the only forward hope, but trust in capital allocation is damaged.

Read what X is saying about $NMRA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • Volume context so you know if today's chatter is normal or unusual
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage CNS biotech advancing navacaprant, a kappa opioid receptor antagonist, for major depressive disorder and neuropsychiatric conditions.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NMRA.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

See how Biotechnology shapes $NMRA

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $NMRA's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IBBiShares Biotechnology ETF
+2.4%YTD
+38.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-180%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-66.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-182%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.30$-0.32+6.3%
Q4 2025Mar 16, 2026$-0.35$-0.34-2.9%
Q3 2025Nov 6, 2025$-0.35$-0.34-2.9%
Q2 2025Aug 6, 2025$-0.33$-0.38+13.2%
Next earningsWed, Aug 5·consensus EPS $-0.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.30$-46.4M
Q4 FY25$0———$-0.35$-47.9M
Q3 FY25$0———$-0.35$-46.6M
Q2 FY25$0———$-0.33$-52.4M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$625K$625K – $625K-$0.93-$1.26 – -$0.659
FY27$5.4M$5.4M – $5.4M-$0.79-$1.14 – -$0.366
FY28$53.6M$53.6M – $53.6M-$0.77-$1.03 – -$0.178
FY29$161.4M$161.4M – $161.4M-$0.43-$0.43 – -$0.437
FY30$355.5M$355.5M – $355.5M$0.10$0.10 – $0.107

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.27%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-21.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-31.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 62.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Know if $NMRA is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellFeb 17Aurora Daljit SinghSee Remarks6.2K sh$22KSellFeb 17Joshua PintoPresident6.0K sh$21KSellFeb 17Paul L BernsSee Remarks9.8K sh$34KSellFeb 17Milligan Michael LeeSee Remarks1.4K sh$5K
+ 10 other (10 awards) in window

See when $NMRA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 158-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 2.05: Restructuring / exit costs · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Neumora Therapeutics Inc. (NMRA) filed an 8-K on June 15, 2026 covering a material definitive agreement (Item 1.01), creation of a direct financial obligation (Item 2.03), triggering of exit/disposal costs (Item 2.05), a Reg FD disclosure (Item 7.01), and other events (Item 8.01). Body unavailable — excerpt cuts off before the specific agreement terms, obligation amount, or exit-cost details are disclosed.

8-KShareholder voteMay 298-K — Item 5.07: Shareholder vote
AI summary

Neumora Therapeutics Inc. (NMRA) reported annual meeting vote results (Item 5.07) in an 8-K filed May 29, 2026. Body unavailable — excerpt cuts off before specific vote tallies are disclosed.

SC 13D/AActivist amendmentApr 1SC 13D/A
8-KPress release / Reg FDFeb 118-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDJan 128-K — Item 7.01: Press release / Reg FD
+ 12 other (4 13Gs · 2 earnings 8-Ks · 2 proxys · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraudgurufocus.com·23h agoNMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraudbusinesswire.com·1d agoNeumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)prnewswire.com·3d agoNeumora Stock Plunges 49% After Late-Stage Depression Drug Failurezacks.com·3d agoPenny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Failbenzinga.com·4d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$ALT$IBRX$QURE$RXRX
Voices on X · top 7 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport